Presentation is loading. Please wait.

Presentation is loading. Please wait.

Regulatory Framework for Phase I & Clinical Pharmacology Studies Funmilayo O. Ajayi, PhD, FCP, FIST Procter & Gamble Cincinnati, Ohio.

Similar presentations

Presentation on theme: "Regulatory Framework for Phase I & Clinical Pharmacology Studies Funmilayo O. Ajayi, PhD, FCP, FIST Procter & Gamble Cincinnati, Ohio."— Presentation transcript:


2 Regulatory Framework for Phase I & Clinical Pharmacology Studies Funmilayo O. Ajayi, PhD, FCP, FIST Procter & Gamble Cincinnati, Ohio

3 Talk Overview n Background Information: –history of drug approval regulation –drug development paradigm n Pre-clinical Studies & Required Data for IND n IND Filing and Clinical Hold Issues n Regulatory Importance of PK and PK/PD Data n Sponsor-Agency Communication

4 Regulation of New Drug Development n n < No effective regulation of human drugs n n Drug removed from market only if adulterated or misbranded n n Requirement of evidence of safety of new drugs n n Requirement of evidence of safety & effectiveness n n FDA Modernization Act: enabled PDUFA n n Medical Device User Fee & Modernization Act n n FDA Amendments Act

5 Substantial Evidence of Effectiveness n n “....Evidence consisting of adequate and well- controlled investigations, including clinical investigations, by qualified scientific experts, that proves the drug will have the effect claimed in its labeling....” Section 505 (d) Fed. Food, Drug & Cosmetic Act, 1962

6 The Drug & Cosmetic Act n n Federal Food, Drug and Cosmetic Act: – –Defines what new drugs are – –States that a new drug must be the subject of an approved new drug application (NDA) n n Food and Drug Administration (FDA): – –Interprets and enforces the laws provided in the Act

7 Regulations & Guidance Documents n n Code of Federal Regulations (21 CFR): – –Written by the FDA to instruct and direct the public in how this law is to be applied – –Outlines the general procedures and requirements that are binding on the FDA n n Guidance Documents / Guidelines: – –Less than regulations but provide detailed guidance for specific situations


9 Types of Preclinical Testing n Short Term Animal Studies (Acute): –Determine pharmacological action and toxicity n Long Term Animal Studies (Chronic): –Look for potential side effects that may result from long term use such as carcinogenicity –Look for reproductive effects

10 Species Selection n Data in two (2) Species is required n Why 2 Species? –Species differences in response n Rodent – almost always rat –Mouse has poorest clinical concordance n Non-rodent – dog, non-human primate n Considerations –Compound supply –Route of administration – e.g. mini-pig for dermal

11 Overview of Study Types n n Safety Pharmacology - functional assessment of major systems n n General Toxicology - target organs, “chronicity of the toxicity” n n Developmental and Reproductive Toxicology - fertility and reproductive performance (Seg I) - embryo/fetal development (Seg II) - neonatal development (Seg III) n n Genetic Toxicology - potential for cancer and heritable mutations n n Carcinogenicity n n Specialty Toxicology

12 Why Preclinical Testing? n Detect overt toxicity n Identify, describe and characterize hazards - reversible? - clinically monitorable? n Establish dose-response estimation of pharmacology & toxic effects n Assess drug distribution to organ systems n Identify metabolic, kinetic and elimination pathways n Assess carcinogenicity, reproductive toxicity and teratogenic potential

13 General Toxicology Data – How Used n n Dose Range n n Provide data for dose selection for definitive study n n Identify major target organs n n Lead selection n n Species selection n n Definitive n n Provide data for dose selection for FIH n n Establish NOEL and MTD n n Define toxicity over duration of study n n Provide TK data


15 Required Duration of Repeated Dose Toxicity Studies to Support Phase I & II Trials Duration of Clinical Trials Minimum Duration of Repeated Dose Toxicity Studies RodentsNon-rodents Single Dose Weeks 2 Weeks Up to 2 Weeks Weeks 2 Weeks Up to 1 Month 1 Month Up to 3 Month 3 Months Up to 6 Month 6 Months > 6 Months 6 Months Chronic

16 What is an IND? n A submission through which a drug sponsor alerts the FDA of its intention to conduct clinical trials with an investigational drug n Application seeking permission to do clinical trials in humans n A request for exemption from the Federal laws that prohibits unapproved drugs from being shipped in interstate commerce

17 Types of INDs

18 IND Regulations/Guidances n 21 Code of Federal Regulations, Section 312 n 1987 IND Rewrite n 1995 Content and Format of Investigational New Drug Applications for Phase I Studies, Including Well-Characterized, Therapeutic, Biotechnology- Derived Products n 1997 ICH M3 Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals

19 When to File an IND n n An IND is filed prior to initiation of clinical trials in humans if it is to evaluate a: -New chemical entity -New indication for marketed agent -New route of administration -New dosage level

20 Common Reasons for Clinical Holds n The IND does not contain sufficient information for the FDA to assess risks to subjects n Additional toxicology data is required - unexpected animal death or toxicity, or positive geno-toxicity n Maximum human dose planned is not supported by toxicology data - e.g. low margin of safety n CMC data is not sufficient or convincing n Investigator is not qualified or ineligible n Clinical Investigator’s Brochure is misleading, erroneous, or incomplete

21 Second Stage in New Drug Development n n Involves three phases of clinical trials of the drug in humans: – –Phase I, II & III

22 Clinical Trial - Phase I n n Initial testing in humans n n Normal volunteers or patients with or at risk for the target disease n n Open-label, dose escalating, safety and tolerance PK studies n n Healthy volunteers and patients n n Intense level of monitoring n n Flexibility in making dosage adjustments

23 Phase I & Clinical Pharmacology Studies Discovery Phase I Phase II Phase III Approval Market Preclinical IND NDA Microsomes CACO2 Permeability Solubility Human Volunteer PK Profiles Patient PK Profiles PK/PD Models and Simulation PopPK Studies IVIVC Models Drug Interactions Disease States Special Pops BE Studies In the 21st Century R&D cost 800M -1.5B/drug

24 Regulations & A Few Guidance Documents n n 21 CFR 320 n n ICH Guidance Documents (15+) n n EMEA Guidance Documents (30+) n n General BA/BE Guidance n n Population PK Guidance n n Exposure/Response Guidance n USDA (Animal Welfare Act) n Good Laboratory Practices n n BCS Guidance n n IVIVC Guidance n n SUPAC Guidance documents (IR, MR and SS)

25 General BA/BE Guidance n n Intended to provide recommendations to sponsors planning to include BA and BE information for orally administered drug products in INDs, NDAs, ANDAs and supplements. n n Also generally applicable to non-orally administered drug products when one relies on systemic exposure measures for BA/BE. * FDA Guidance: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations

26 PK/PD: Implication in New Formulations and/or New Doses of Approved Drugs* n n Where blood levels... are not very different, it may be possible to conclude... is effective on the basis of pharmacokinetic data alone. n n Even if blood levels are quite different, if there is a well- understood relationship between blood concentration and response (PK/PD),..., it may be possible to conclude... is effective on the basis of pharmacokinetic data without an additional clinical efficacy trial. * *Guidance for Industry “Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products”, May 1998

27 Regulatory Support for Pharmacokinetics / Pharmacodynamic Data n n FDAMA Sec Clinical investigations: – –Support of one adequate and well-controlled clinical investigation by “confirmatory evidence” comprising PK or PK/PD

28 PK/PD - Why Bother? FDAMA, Sec. 115 Clinical Investigations CONGRESSIONAL COMMITTEE REPORTS* “confirmatory evidence” = “scientifically sound data from any investigation in the NDA that provides substantiation as to the safety and effectiveness of the new drug” n n Confirmatory evidence =“consisting of earlier clinical trials, pharmacokinetic data, or other appropriate scientific studies” *House Commerce Committee, 10/7/97, and Committee on Disagreeing votes of the two Houses, 11/9/97

29 Regulatory Support for Pharmacokinetics FDA Modernization Act of 1997 (“FDAMA)” n n Sec Pediatric studies of drugs – –PK bridging studies to support use in pediatric population

30 Pharmacokinetics - Why Bother? Pediatric Labeling Regulations (21 CFR ) “ FDA may approve a drug for pediatric use based on …studies in adults, with other information supporting pediatric use …. Additional information supporting pediatric use must ordinarily include data on the pharmacokinetics of the drug in the pediatric population ….Other information, such as data on pharmacodynamic studies …..”

31 Attrition On The R&D Process Preclinical Pharmacology Preclinical Safety 7,000,000 Compounds Screened Idea Drug Years ~100 Discovery Approaches Products Discovery Exploratory Development Full Development Phase I Phase IIPhase III Clinical Pharmacology & Safety

32 CHANGING THE INDUSTRY/FDA INTERPHASE: A CRITICAL PATH OPPORTUNITY n n Target Validation n n Screening n n Lead Development n n Pre-Lead n n Lead n n First in Human-FDA dialogue n n Proof of Concept-FDA dialogue n n Full Development-FDA dialogue Molecular Sciences And Technologies Pharmacology Experimental Medicine Clinical Development Expanded Scope: Expanded Scope: Exploratory IND Microdosing PK/PD Biomarkers Desired Human Exposure Proof of Non-viability Proof of Concept Exploratory IND Microdosing PK/PD Biomarkers Desired Human Exposure Proof of Non-viability Proof of Concept

33 Critical Path Agenda and Opportunities n n Need for a paradigm shift to improve the efficiency of clinical drug development n n Model-based drug development approaches are powerful tools to improve clinical drug development, regulatory guidance and the quality of NDA submissions n n Model-based drug development such as: – – drug and disease modeling – – exposure-response modeling n n Importance of FDA and academia to lead the widespread adoption of the tools and concepts in the pharmaceutical industry

34 Drug/Disease Modeling and Clinical Trial Simulation: A Well-Established Strategy Results GraphicsGraphics Statistical Analysis Interface to SAS, Etc. Interface to SAS, Etc. –Drug –Disease –Patients –Drug –Disease –Patients DrugModel ReplicationsReplications Trial Design Strategies StructureScheduleEndpointsStructureScheduleEndpoints Subject Selection ComplianceDropout ComplianceDropout Modify Drug Model Modify Trial Design

35 Population Pharmacokinetic & Dynamic Modeling: A Fundamental Tool to Characterize E-R Relationships Extensive PKSparse PK Time (h) Drug Concentration Mixed Effects Modeling Exposure EfficacySafety Choice of Dosage Regimen

36 Advanced Quantitative Modeling: Implication in Drug Development & Approval Process n n Exposure vs. response (efficacy & safety) relationship in dose selection n n Computer-assisted simulation of clinical trials to address study design and data analysis issues n n Population PK/PD data analysis to understand variability and to provide evidence for label claims n n Dose adjustment in special populations (hepatic, renal, gender, age and drug interactions) – –based on inter-subject variability and risk assessment

37 Sponsor-Regulatory Agency Communication The goal has always been to find ways to achieve more frequent and more direct communication with reviewers. Also to understand the…. 1. What? 2. When? 3. How? 4. Why? Communication brings added value or benefits to the drug development process

38 Communication: On What? n n Questions during the drafting of study protocols – –more likely to arise earlier than later in clinical development when input can be of high value (e.g., specific study) n n Review of finalized, individual study protocols or reports – –often occurs right before or after next study begins – –it is important to know when this will add value during IND phase n n Comments on overall clinical development program – –could be of value & provide context for role of study in overall program

39 Communication: When? n n Pre-IND – –enables discussion of issues related to specific study design before protocol is finalized – e.g. dosing strategy, proposed clinical pharmacology program n n EoP2A – –focus on questions or issues related to key E/R parameters of interest, data analysis, dose-ranging and proposed study designs for phase 2B and 3 – –discuss special more complex issues in overall clinical development strategy (e.g., QT studies, pharmacogenetic studies, drug interactions with transporters)

40 Communication: How? Formal meetings: desired feedback may be more urgent given the time to set up meetings

41 Communication: How? n n Informal Meetings – e.g. teleconferences – –policies regarding direct communication between reviewers and sponsors varies with medical division – –most medical divisions want sponsor to go through project managers for specific review questions – –rationale is that medical divisions are better able to keep track of decisions made - especially those that impact or influence efficacy/safety or CMC issues

42 Communication: Why? n n Open, timely, exchange of ideas between Sponsor and regulatory agencies n n Obtain Agency’s views on questions / issues n n Opportunity for specific questions to be addressed - e.g., # of special population or interaction studies n n Minimize regulatory decision surprises n n Facilitates good review management principles

43 Effective Communication Strategy n n Submit IND protocols for review at least 90 days before anticipated start of study n n State in cover letter that review of protocol &/or study report is requested n n Provide adequate information / data – –facilitates review & response to Questions n n Describe role of study in overall development program and/or potential regulatory outcomes (e.g., label claim)

44 Questions?

Download ppt "Regulatory Framework for Phase I & Clinical Pharmacology Studies Funmilayo O. Ajayi, PhD, FCP, FIST Procter & Gamble Cincinnati, Ohio."

Similar presentations

Ads by Google